There are currently 1271 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division, Cleveland, Ohio
Conditions: Psoriatic Arthritis
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Cleveland, Ohio
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/29/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio +1 locations
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
NCT05835466
Recruiting
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: The Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Register for Updates
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
NCT05610852
Recruiting
This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.
Gender:
MALE
Ages:
19 years and above
Trial Updated:
07/29/2025
Locations: Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Prostate Adenocarcinoma, Prostate Cancer
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/29/2025
Locations: Research Site, Cleveland, Ohio
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Rainbow Babies And Children's Hospital- Site Number : 8400011, Cleveland, Ohio
Conditions: Type 1 Diabetes
Register for Updates
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT06184750
Recruiting
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
07/29/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Register for Updates
Positive Processes and Transition to Health (PATH)
NCT06093906
Recruiting
The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Healt... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution
NCT06795035
Recruiting
The goal of this observational study to measure the heart's microvascular function in the setting of a myocardial infarction (MI), or heart attack, using a method called continuous saline thermodilution (CST). The participants will include people who are experiencing MI from sudden and complete blockage of a coronary artery requiring immediate balloon and/or stent therapy. After getting the balloon and/or stent therapy, participants will have their heart's microvascular system tested using CST.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: ST Elevation Myocardial Infarction, Coronary Microvascular Dysfunction, Microvascular Obstruction
Register for Updates
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
Recruiting
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Taussig Cancer Center - Cleveland Clinic, Cleveland, Ohio
Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Register for Updates